Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nemirovsky

Showing results (271-280 of 294) with videos related to

Pageof 30
Sort By:
Blood Cancer Journal|November 2, 2025
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myelomaEric Jurgens, Tala Shekarkhand, Colin Rueda, et al.
Blood Cancer Journal|April 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myelomaHamza Hashmi, Tara Sebastian, Sridevi Rajeeve, et al.
Blood Cancer Journal|May 31, 2024
Comparison of infectious complications with BCMA-directed therapies in multiple myelomaKarthik Nath, Tala Shekarkhand, David Nemirovsky, et al.
Medicina|May 23, 2020
[Consenso Argentino Intersociedades de Infección Urinaria 2018-2019 - Parte I]Corina Nemirovsky, María José López Furst, Daniel Pryluka, et al.
Plos One|October 8, 2021
Clinical characteristics and outcomes of hospitalized patients with SARS-CoV-2 infection in a Latin American country: Results from the ECCOVID multicenter prospective studyEzequiel Cordova, Analia Mykietiuk, Omar Sued, et al.
Hemasphere|December 1, 2025
Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphomaEfrat Luttwak, David Nemirovsky, Sean M Devlin, et al.
Blood Advances|March 6, 2025
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up DosingCarlyn R Tan, Alice X Wang, David Nemirovsky, et al.
Blood Advances|May 2, 2025
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple MyelomaBenjamin O Adegbite, Carlyn Rose Tan, Tala Shekarkhand, et al.
JAMA Oncology|May 15, 2025
Barriers to Chimeric Antigen Receptor T-Cell TherapyYannis K Valtis, Kuo-Kai Chin, David Nemirovsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenanceRoss S Firestone, Anish K Simhal, Devin McAvoy, et al.
Pageof 30

Showing results (271-280 of 294) with videos related to

Sort By:
Pageof 30
Blood Cancer Journal|November 2, 2025
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myelomaEric Jurgens, Tala Shekarkhand, Colin Rueda, et al.
Blood Cancer Journal|April 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myelomaHamza Hashmi, Tara Sebastian, Sridevi Rajeeve, et al.
Blood Cancer Journal|May 31, 2024
Comparison of infectious complications with BCMA-directed therapies in multiple myelomaKarthik Nath, Tala Shekarkhand, David Nemirovsky, et al.
Medicina|May 23, 2020
[Consenso Argentino Intersociedades de Infección Urinaria 2018-2019 - Parte I]Corina Nemirovsky, María José López Furst, Daniel Pryluka, et al.
Plos One|October 8, 2021
Clinical characteristics and outcomes of hospitalized patients with SARS-CoV-2 infection in a Latin American country: Results from the ECCOVID multicenter prospective studyEzequiel Cordova, Analia Mykietiuk, Omar Sued, et al.
Hemasphere|December 1, 2025
Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphomaEfrat Luttwak, David Nemirovsky, Sean M Devlin, et al.
Blood Advances|March 6, 2025
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up DosingCarlyn R Tan, Alice X Wang, David Nemirovsky, et al.
Blood Advances|May 2, 2025
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple MyelomaBenjamin O Adegbite, Carlyn Rose Tan, Tala Shekarkhand, et al.
JAMA Oncology|May 15, 2025
Barriers to Chimeric Antigen Receptor T-Cell TherapyYannis K Valtis, Kuo-Kai Chin, David Nemirovsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenanceRoss S Firestone, Anish K Simhal, Devin McAvoy, et al.
Pageof 30